Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 17/20 | 0.79 |
| ▸ | ADRB1 | P08588 | 9/20 | 0.79 |
| ▸ | ADRB3 | P13945 | 6/20 | 0.79 |
| ▸ | PGR | P06401 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3838751 | 1.00 | ADRB2 (0.79) | ADRB2ADRB1ADRB3PGRDRD2 | |
| SCHEMBL3838033 | 1.00 | ADRB2 (0.79) | ADRB2ADRB1ADRB3PGRDRD2 | |
| SCHEMBL3840237 | 0.90 | ADRB2 (0.76) | ADRB2ADRB1ADRB3PGRDRD2 | |
| SCHEMBL3840242 | 0.90 | ADRB2 (0.76) | ADRB2ADRB1ADRB3PGRDRD2 | |
| SCHEMBL3840455 | 0.90 | ADRB2 (0.76) | ADRB2ADRB1ADRB3PGRDRD2 | |
| SCHEMBL774948 | 0.88 | ADRB2 (1.00) | ADRB2ADRB1ADRB3PGRDRD2 | |
| SCHEMBL13617661 | 0.87 | ADRB2 (0.62) | ADRB2ADRB1ADRB3 | |
| SCHEMBL30254965 | 0.85 | ADRB2 (0.77) | ADRB2ADRB1ADRB3PGRDRD2 | |
| SCHEMBL14260754 | 0.85 | ADRB2 (0.77) | ADRB2ADRB1ADRB3PGRDRD2 | |
| SCHEMBL3838435 | 0.85 | ADRB2 (0.85) | ADRB2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1641465-B1 | COMBINATIONS OF AN ARYL ANILINE BETA-2 ADRENERGIC RECEPTOR AGONIST AND A CORTICOSTEROID | THERAVANCE INC (US) | 2009-11-04 | — | — | EP | claimed |
| EP-1446379-B1 | ARYL ANILINE BETA-2 ADRENERGIC RECEPTOR AGONISTS | THERAVANCE INC (US) | 2009-04-29 | — | — | EP | claimed |
| EP-1641465-A2 | COMBINATIONS OF AN ARYL ANILINE BETA-2 ADRENERGIC RECEPTOR AGONIST AND A CORTICOSTEROID | Theravance, Inc. (US) | 2006-04-05 | — | — | EP | claimed |
| WO-2005025555-A2 | COMBINATIONS OF AN ARYL ANILINE BETA-2 ADRENERGIC RECEPTOR AGONIST AND A CORTICOSTEROID | THERAVANCE, INC. (US) | 2005-03-24 | — | — | WO | claimed |
| EP-1446379-A1 | ARYL ANILINE BETA-2 ADRENERGIC RECEPTOR AGONISTS | Theravance, Inc. (US) | 2004-08-18 | — | — | EP | claimed |
| US-20040063755-A1 | Aryl aniline beta2 adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-04-01 | — | — | US | claimed |
| US-20040059116-A1 | Aryl aniline beta2 adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-03-25 | — | — | US | claimed |
| US-6670376-B1 | Asthma or chronic obstructive pulmonary disease; pre-term labor, neurological and cardiac disorders, inflammation; N-(2-(4-(3-phenyl-4-methoxyphenyl) aminophenyl)ethyl)-(R)-2-hydroxy-2-(3- hydroxymethyl-4-hydroxyphenyl)ethylamine | THERAVANCE, INC. | 2003-12-30 | — | — | US | claimed |
| US-20030229058-A1 | Aryl aniline beta2 adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2003-12-11 | — | — | US | claimed |
| US-6653323-B2 | Such as n-(2-(4-(3-phenyl-4-methoxyphenyl)aminophenyl)ethyl)--2-hydroxy-2-(3 -hydroxymethyl-4-hydroxyphenyl)ethylamine; pulmonary diseases | THERAVANCE, INC. | 2003-11-25 | — | — | US | claimed |
| US-20030153597-A1 | Aryl aniline beta2 adrenergic receptor agonists | GLOBAL CASH ACCESS, L.L.C. | 2003-08-14 | — | — | US | claimed |
| WO-2003042164-A1 | ARYL ANILINE BETA-2 ADRENERGIC RECEPTOR AGONISTS | THERAVANCE, INC (US) | 2003-05-22 | — | — | WO | claimed |
| WO-2003042160-A1 | ARYL ANILINE BETA-2 ADRENERGIC RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2003-05-22 | — | — | WO | claimed |
| EP-1641465-B1 | COMBINATIONS OF AN ARYL ANILINE BETA-2 ADRENERGIC RECEPTOR AGONIST AND A CORTICOSTEROID | THERAVANCE INC (US) | 2009-11-04 | — | — | EP | disclosed |
| EP-1641465-B1 | COMBINATIONS OF AN ARYL ANILINE BETA-2 ADRENERGIC RECEPTOR AGONIST AND A CORTICOSTEROID | THERAVANCE INC (US) | 2009-11-04 | — | — | EP | disclosed |
| US-7582765-B2 | Aryl aniline β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-6653323-B2 | Such as n-(2-(4-(3-phenyl-4-methoxyphenyl)aminophenyl)ethyl)--2-hydroxy-2-(3 -hydroxymethyl-4-hydroxyphenyl)ethylamine; pulmonary diseases | THERAVANCE, INC. | 2003-11-25 | — | — | US | disclosed |
| US-20030153597-A1 | Aryl aniline beta2 adrenergic receptor agonists | GLOBAL CASH ACCESS, L.L.C. | 2003-08-14 | — | — | US | disclosed |
| WO-2003042164-A1 | ARYL ANILINE BETA-2 ADRENERGIC RECEPTOR AGONISTS | THERAVANCE, INC (US) | 2003-05-22 | — | — | WO | disclosed |
| WO-2003042160-A1 | ARYL ANILINE BETA-2 ADRENERGIC RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040059116-A1 | Aryl aniline beta2 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | ADRB2 1/4885ADRB1 2/4885ADRB3 3/4885 |
| US-20030153597-A1 | Aryl aniline beta2 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | ADRB2 1/4885ADRB1 2/4885ADRB3 3/4885 |
| US-20040063755-A1 | Aryl aniline beta2 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | ADRB2 1/4885ADRB1 2/4885ADRB3 3/4885 |
| US-20030229058-A1 | Aryl aniline beta2 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | ADRB2 1/4885ADRB1 2/4885ADRB3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.